Case and Commentary
Nov 2004

Clinical Trials and End-of-Life Decision Making, Commentary 2

Lucy Godley, MD, PhD
Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.

Case

Alice Wilson's daughter finally convinced her mother to make an appointment with the family physician 2 weeks after Alice's 65th birthday. Alice organized a garden party to celebrate, and it was a great success with all 5 children, 14 grandchildren, and most of her neighbors in attendance. Alice attributed her 20-pound weight loss and fatigue to the preparations for the party. She didn't tell anyone about the pain in her stomach that had been keeping her awake off-and-on for 6 months. It was only after the party—when she could no longer explain her fatigue—that Alice reluctantly agreed to see her physician.

Instead of a garden party, Alice spent her 66th birthday in the hospital recovering from her second surgery, this time to remove 3 suspicious lymph nodes and intra-abdominal metastases seeded from the advanced adenocarcinoma removed from her colon the previous summer. Since the first surgery, one of her children or her husband Will have been driving Alice for her weekly rounds of chemotherapy with Dr. Tseng, her oncologist. Almost a year later, he knows the names of all 5 children and most of the grandchildren, including the 2-week-old granddaughter named Alice .

Alice resumed her chemotherapy 3 weeks after the second surgery. At every visit she asks Dr. Tseng the same question: "What are my numbers, Doctor?" she wants to know. Immediately following the surgery Alice 's CEA levels dropped, and for a few weeks she would joke with the nurses who started her IV. "Careful with that," she would say, smiling, as one of them slipped a needle into the vein behind her elbow. Several months later the jokes stopped as her CEA values began to creep up again, gradually at first and then faster and faster.

At a special appointment between rounds of chemotherapy, Dr. Tseng tells Alice that the surgery and chemotherapy are slowing down the cancer growth, but they haven't been able to stop it. Alice doesn't say anything. She is tired all the time, she doesn't want to eat, the pain in her stomach still keeps her awake at night, and she has lost an additional 25 pounds. She has not yet been able to take baby Alice for a walk because she is too tired to push the stroller more than a few blocks. Dr. Tseng hesitates. Should he tell Alice about Zorvax, a new angiogenesis inhibitor in Phase II clinical trials? Clinically, Alice would be an ideal patient to enroll in the trial, and the latest publications about Zorvax indicate that many patients respond favorably. "There is something else we can try," he tells her, as he explains about the experimental medication. "This drug works in a different way than your current chemotherapy," he says. "It might be able to help slow down the cancer and give you more energy." Alice pauses for a moment. "I don't know," she says at last. "I don't know how much more chemotherapy I want to do. Will I still be so tired all of the time? I just don't know. What do you think I should do?"

Commentary 2

This case illustrates a common situation in the treatment of cancer patients—deciding when to continue therapy aimed at disease control and when to initiate measures designed to maximize patient comfort. In this example, the patient is a 66-year-old woman who has been treated aggressively with multiple surgeries and numerous chemotherapy regimens for advanced-stage colon cancer. This is a realistic scenario, since there are many active chemotherapy agents available for colon cancer and several different ways to combine them. The patient, now tired, worn out, and in pain, asks her doctor whether she should continue therapy directed at controlling her disease.

Chemotherapy treatment today is much better tolerated than in years past, thanks to numerous agents that support cancer patients [1]. Several growth factors are available that stimulate white blood cell production by the bone marrow (G-CSF and GM-CSF), thus allowing chemotherapy regimens to be given with high intensity and on accelerated schedules with improved efficacy [2]. Chemotherapy-induced anemia can be treated with erythropoietin and its derivatives, which stimulate red blood cell production, alleviate the tiredness associated with prolonged chemotherapy, and augment chemotherapy and radiation effectiveness [3]. Several new and highly effective agents are available to treat chemotherapy-induced nausea and vomiting, making chemotherapy much more tolerable [4]. Cannabinoids can stimulate the appetite as well as control nausea and vomiting. Many narcotic and non-narcotic analgesic agents are available to treat cancer-associated pain. For example, radiation can often be used to palliate the pain associated with bony metastases. In the case at hand, one wonders whether Mrs. Wilson's symptoms of tiredness, anorexia, and pain have been adequately addressed. She has been seeing her oncologist weekly for some time, so there should have been ample opportunity to discuss these issues. Oncologists should aggressively manage the symptoms associated with cancer therapy in the interests of improving quality of life for patients.

When oncologists are faced with questions like Mrs. Wilson's—should she try an experimental therapy or just accept palliative care—they must use careful judgment in answering. Since physicians in private practice receive direct financial payment based on the administration of chemotherapy, oncologists must conscientiously separate clinical assessment of the patient from the financial needs of their practices, and they must be clear with themselves and their patients that patient welfare—not personal interest—is their primary concern. Physicians in academic centers may feel less of a direct financial reward from treating patients. Nonetheless, all physicians must ask themselves when treating relapsed patients, "When should we change the focus of care from one of controlling the disease to one of comforting the symptoms?"

Patients whose disease progresses after they have received standard treatment regimens often become candidates for investigational agents. Drugs in Phase I testing are being studied for toxicity in humans, while drugs in Phase II testing are being studied for efficacy. The decision to enter into a clinical trial must be preceded by full disclosure to the patient as to the purposes of the study. Patients should be given written consent forms to read and discuss before entering into the study. They should have realistic expectations as to what outcomes they seek to gain from the trial. Achieving this can be difficult with patients who are in denial about their disease and its prognosis, but physicians must be forthright and persistent about realistic expectations.

Hospice and programs with similar goals accept patients with an approximate life expectancy of 6 months to 1 year [5]. Unfortunately, oncologists are notorious for referring patients to such programs when they have only a few days or hours to live. Such late referrals do not allow patients or family members to experience the benefit of the superb care provided by these programs. Comfort-care approaches should not be seen as "giving up" on a patient but as active management of patients. Physicians and nurses should help patients accept that they are at the end of their lives and that the focus of care will now shift to controlling their symptoms instead of the primary disease process.

Each patient is unique and has his or her own style of decision making. Physicians should try to incorporate patient and family goals into each decision. In this case, when Mrs. Wilson asks, "What do you think I should do?" Dr. Tseng can be most helpful by redirecting the question to her and saying, "Well, that depends on what your goals are at this point." The doctor, patient, and family members can then discuss expectations of further chemotherapy versus comfort-level approaches. If Mrs. Wilson wants to do everything medically possible to treat her disease, then she might decide to continue on with a Phase I or II study. If, however, she feels that she is getting incrementally less and less benefit with each treatment and would prefer staying home and maximizing her comfort at this time, she might choose to stop chemotherapy and enter a hospice program.

The most appropriate and informed decision will result from open, candid discussion among the patient, her family, and her doctor, after realistic expectations have been outlined. Once engaged in such a conversation, Mrs. Wilson may again ask Dr. Tseng what he thinks she should do. At that point, Dr. Tseng may feel comfortable expressing his opinion directly. If Mrs. Wilson were my patient, I would speak with her and her family and encourage her to consider entering a hospice-type program.

References

  1. Balducci L. New paradigms for treating elderly patients with cancer: the comprehensive geriatric assessment and guidelines for supportive care. J Support Oncol. 2003; 1:30 -37.

  2. Glaspy JA. Hematopoietic management in oncology practice. Oncology. (Huntingt) 2003;17:1593-1603.

  3. Ferrario E, Ferrari L, Bidoli P, et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev. 2004;30(6):563-575.
  4. Constenla M. 5-HT3 Receptor Antagonists for Prevention of Late Acute-Onset Emesis. Ann Pharmacother. 2004;38(10):1683-1691.
  5. Matulonis UA. End of life issues in older patients. Semin Oncol. 2004;31(2):274-281.

Citation

Virtual Mentor. 2004;6(11):479-481.

DOI

10.1001/virtualmentor.2004.6.11.ccas1-0411.

The people and events in this case are fictional. Resemblance to real events or to names of people, living or dead, is entirely coincidental. The viewpoints expressed on this site are those of the authors and do not necessarily reflect the views and policies of the AMA.